CCEL Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of 9.58% compared to Cryo-Cell International, Inc.'s net margin of 0.11%. Cryo-Cell International, Inc.'s return on equity of -- beat Astrana Health, Inc.'s return on equity of 1.85%.

Cryo-Cell International, Inc. has a consensus price target of $8.50, signalling upside risk potential of 148.03%. On the other hand Astrana Health, Inc. has an analysts' consensus of $35.6667 which suggests that it could grow by 89.92%. Given that Cryo-Cell International, Inc. has higher upside potential than Astrana Health, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Astrana Health, Inc..

Cryo-Cell International, Inc. has a beta of 0.701, which suggesting that the stock is 29.861% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.555%.

Cryo-Cell International, Inc. has a quarterly dividend of $0.15 per share corresponding to a yield of 18.97%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International, Inc. pays 510.2% of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

Cryo-Cell International, Inc. quarterly revenues are $7.8M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Cryo-Cell International, Inc.'s net income of $749.4K is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, Cryo-Cell International, Inc.'s price-to-earnings ratio is 498.00x while Astrana Health, Inc.'s PE ratio is 98.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International, Inc. is 0.88x versus 0.32x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novo Integrated Sciences, Inc. has a net margin of 9.58% compared to Cryo-Cell International, Inc.'s net margin of -86.61%. Cryo-Cell International, Inc.'s return on equity of -- beat Novo Integrated Sciences, Inc.'s return on equity of -49.15%.

Cryo-Cell International, Inc. has a consensus price target of $8.50, signalling upside risk potential of 148.03%. On the other hand Novo Integrated Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Cryo-Cell International, Inc. has higher upside potential than Novo Integrated Sciences, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Novo Integrated Sciences, Inc..

Cryo-Cell International, Inc. has a beta of 0.701, which suggesting that the stock is 29.861% less volatile than S&P 500. In comparison Novo Integrated Sciences, Inc. has a beta of 1.479, suggesting its more volatile than the S&P 500 by 47.909%.

Cryo-Cell International, Inc. has a quarterly dividend of $0.15 per share corresponding to a yield of 18.97%. Novo Integrated Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International, Inc. pays 510.2% of its earnings as a dividend. Novo Integrated Sciences, Inc. pays out -- of its earnings as a dividend.

Cryo-Cell International, Inc. quarterly revenues are $7.8M, which are larger than Novo Integrated Sciences, Inc. quarterly revenues of $3.2M. Cryo-Cell International, Inc.'s net income of $749.4K is higher than Novo Integrated Sciences, Inc.'s net income of -$2.7M. Notably, Cryo-Cell International, Inc.'s price-to-earnings ratio is 498.00x while Novo Integrated Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International, Inc. is 0.88x versus 0.00x for Novo Integrated Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Health Care Organization, Inc. has a net margin of 9.58% compared to Cryo-Cell International, Inc.'s net margin of 14.05%. Cryo-Cell International, Inc.'s return on equity of -- beat Pacific Health Care Organization, Inc.'s return on equity of 11.97%.

Cryo-Cell International, Inc. has a consensus price target of $8.50, signalling upside risk potential of 148.03%. On the other hand Pacific Health Care Organization, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Cryo-Cell International, Inc. has higher upside potential than Pacific Health Care Organization, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Pacific Health Care Organization, Inc..

Cryo-Cell International, Inc. has a beta of 0.701, which suggesting that the stock is 29.861% less volatile than S&P 500. In comparison Pacific Health Care Organization, Inc. has a beta of 0.126, suggesting its less volatile than the S&P 500 by 87.368%.

Cryo-Cell International, Inc. has a quarterly dividend of $0.15 per share corresponding to a yield of 18.97%. Pacific Health Care Organization, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.10 per share. Cryo-Cell International, Inc. pays 510.2% of its earnings as a dividend. Pacific Health Care Organization, Inc. pays out -- of its earnings as a dividend.

Cryo-Cell International, Inc. quarterly revenues are $7.8M, which are larger than Pacific Health Care Organization, Inc. quarterly revenues of $1.6M. Cryo-Cell International, Inc.'s net income of $749.4K is higher than Pacific Health Care Organization, Inc.'s net income of $223K. Notably, Cryo-Cell International, Inc.'s price-to-earnings ratio is 498.00x while Pacific Health Care Organization, Inc.'s PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International, Inc. is 0.88x versus 2.53x for Pacific Health Care Organization, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

WW International has a net margin of 9.58% compared to Cryo-Cell International, Inc.'s net margin of -38.91%. Cryo-Cell International, Inc.'s return on equity of -- beat WW International's return on equity of --.

Cryo-Cell International, Inc. has a consensus price target of $8.50, signalling upside risk potential of 148.03%. On the other hand WW International has an analysts' consensus of $1.10 which suggests that it could grow by 340.71%. Given that WW International has higher upside potential than Cryo-Cell International, Inc., analysts believe WW International is more attractive than Cryo-Cell International, Inc..

Cryo-Cell International, Inc. has a beta of 0.701, which suggesting that the stock is 29.861% less volatile than S&P 500. In comparison WW International has a beta of 1.298, suggesting its more volatile than the S&P 500 by 29.755%.

Cryo-Cell International, Inc. has a quarterly dividend of $0.15 per share corresponding to a yield of 18.97%. WW International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International, Inc. pays 510.2% of its earnings as a dividend. WW International pays out -- of its earnings as a dividend.

Cryo-Cell International, Inc. quarterly revenues are $7.8M, which are smaller than WW International quarterly revenues of $186.6M. Cryo-Cell International, Inc.'s net income of $749.4K is higher than WW International's net income of -$72.6M. Notably, Cryo-Cell International, Inc.'s price-to-earnings ratio is 498.00x while WW International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International, Inc. is 0.88x versus 0.03x for WW International. Usually stocks with elevated PS ratios are considered overvalued.